In: Interactive CardioVascular and Thoracic Surgery, 2018, vol. 27, no. 3, p. 427-436
|
In: European Journal of Pharmaceutics and Biopharmaceutics, 2019, vol. 139, p. 253–261
Resiquimod (R848), a member of the imidazoquinoline family, is a Toll-like receptor 7/8 agonist with high potency for cancer immunotherapy. However, tolerance induction and adverse effects limit its development as a drug. Encapsulation in a polymer matrix can circumvent these limitations, as shown in our formerly published approach where R848 was loaded into polylactic acid (PLA)-based...
|
In: Targeted Oncology, 2013, vol. 8, no. 4, p. 225-230
|
In: International Journal of Pharmaceutics, 2018, vol. 535, no. 1, p. 444–451
Small-molecule agonists for the Toll-like receptors (TLR) 7 and 8 are effective for the immunotherapy of skin cancer when used as topical agents. Their systemic use has however been largely unsuccessful due to dose-limiting toxicity. We propose a polymer-based nanodelivery system to target resiquimod, a TLR7 ligand, to the lymph node in order to focus the immunostimulatory activity and to...
|